APAF1 and breast cancer: Bortezomib is a proteasome inhibitor that can restore the expression of apoptotic proteins such as Apaf-1 and prevent the degradation of cytosolic cyt c released by Docetaxel, thereby triggering the intrinsic apoptotic pathway and promoting cancer cell death, enhancing the cytotoxic effect of docetaxel on MCF7 breast cancer cells, and it also helps to overcome chemoresistance [53].